特朗普签署行政令，要求处方药在美国降价

Core Viewpoint - The executive order signed by President Trump aims to lower prescription drug prices in the U.S. to align with prices in other developed countries, suggesting a potential price reduction of at least 59% and up to 80% or 90% in certain cases [1] Group 1: Price Reduction Measures - The executive order mandates pharmaceutical companies to reduce drug prices, indicating a significant shift in pricing strategy [1] - The proposed price reductions are based on comparisons with prices in other developed nations, highlighting the disparity in drug pricing [1] Group 2: Structural Issues and Trade Implications - Analysts suggest that the high drug prices in the U.S. are due to structural reasons, indicating deeper systemic issues within the healthcare and pharmaceutical sectors [1] - If European Union companies refuse to adjust their drug prices, potential U.S. tariff measures could lead to trade tensions and exacerbate drug shortages [1]